Vinva Investment Management Ltd Has $5.32 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

Vinva Investment Management Ltd grew its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 216.5% during the third quarter, HoldingsChannel reports. The firm owned 98,403 shares of the biotechnology company’s stock after buying an additional 67,309 shares during the quarter. Vinva Investment Management Ltd’s holdings in BioMarin Pharmaceutical were worth $5,316,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of BMRN. NewEdge Advisors LLC grew its stake in BioMarin Pharmaceutical by 11.5% in the 1st quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company’s stock valued at $266,000 after buying an additional 388 shares during the last quarter. Empowered Funds LLC lifted its position in BioMarin Pharmaceutical by 207.4% during the 1st quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company’s stock worth $850,000 after acquiring an additional 8,112 shares during the last quarter. Focus Partners Wealth boosted its holdings in BioMarin Pharmaceutical by 70.2% during the first quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company’s stock valued at $835,000 after acquiring an additional 4,876 shares during the period. Sivia Capital Partners LLC boosted its holdings in BioMarin Pharmaceutical by 33.0% during the second quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company’s stock valued at $244,000 after acquiring an additional 1,102 shares during the period. Finally, Envestnet Asset Management Inc. grew its position in shares of BioMarin Pharmaceutical by 15.4% in the second quarter. Envestnet Asset Management Inc. now owns 50,753 shares of the biotechnology company’s stock valued at $2,790,000 after purchasing an additional 6,777 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BMRN has been the topic of a number of recent analyst reports. Sanford C. Bernstein lifted their price objective on BioMarin Pharmaceutical from $90.00 to $94.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Leerink Partners lowered BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $82.00 to $60.00 in a report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of BioMarin Pharmaceutical in a research report on Monday, December 29th. Stifel Nicolaus set a $68.00 price target on BioMarin Pharmaceutical in a report on Tuesday, February 24th. Finally, Oppenheimer cut their price target on BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating for the company in a report on Tuesday, February 24th. Fifteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $89.64.

BioMarin Pharmaceutical Trading Up 0.9%

Shares of BioMarin Pharmaceutical stock opened at $61.12 on Monday. BioMarin Pharmaceutical Inc. has a 52-week low of $50.76 and a 52-week high of $73.51. The firm has a market capitalization of $11.75 billion, a PE ratio of 34.34, a price-to-earnings-growth ratio of 0.53 and a beta of 0.25. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.21 and a quick ratio of 3.50. The company’s fifty day moving average price is $58.92 and its two-hundred day moving average price is $56.25.

Insider Buying and Selling at BioMarin Pharmaceutical

In related news, EVP Gregory R. Friberg sold 6,326 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $60.38, for a total value of $381,963.88. Following the sale, the executive vice president owned 37,578 shares of the company’s stock, valued at $2,268,959.64. The trade was a 14.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.85% of the company’s stock.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.